Harrow, Inc. reported second quarter 2026 financial results with total revenue of $70.7 million, an increase of 11% year over year and 60% sequentially. The company posted a GAAP net loss of $17.3 million and Adjusted EBITDA of negative $1.2 million for the quarter. Harrow reiterated its full-year 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA. Key product highlights included VEVYE revenue of $29.4 million, up approximately 58% year over year, and IHEEZO unit demand reaching a record 65,477 units, up 34% year over year. The company announced the acquisition of TYRVAYA from Viatris, expected to close in the second half of 2026, and launched BYOOVIZ, a biosimilar to LUCENTIS. Harrow holds $83.9 million in cash as of June 30, 2026. The company operates in the ophthalmic disease management industry, providing pharmaceutical solutions for conditions affecting the front and back of the eye.